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H eart disease continues to be a major cause of morbidity and mortality worldwide. According to a recent report from American Heart Association, death caused by cardiovascular diseases accounts for 1 in every 3 deaths in North America. 1 Fibrosis is a common feature of various cardiomyopathies including dilated and hypertrophic cardiomyopathy, and myocardial infarction (MI), although the type of fibrosis differs in these diseases. Myocardial fibrosis in hypertrophic and DCM is reactive fibrosis, whereas fibrosis in MI is reparative fibrosis as it replaces the lost cardiomyocytes secondary to ischemia. 2 Reparative fibrosis in the infarcted myocardium is mediated by inflammatory influx, 3 and transformation of fibroblasts to myofibroblast 4, 5 that rapidly populate the affected area, produce, and deposit extracellular matrix (ECM) and form a fibrotic scar. The mechanism underlying reactive fibrosis is less explored as it occurs in the absence of cardiomyocyte loss. Fibrosis, regardless of its initiating cause, unfavorably alters cardiac structure and function and can lead to heart failure, 6, 7 and as such, understanding its underlying molecular mechanism is essential in developing effective therapies for patients with heart failure. 8, 9 Fibrosis is the result of adverse remodeling and excess deposition of the ECM, primarily fibrillar collagens type I and type III. Tissue inhibitor of metalloproteinases (TIMPs) maintain the homeostatic balance of myocardial ECM by inhibiting the activated matrix metalloproteinases (MMPs). Among the 4 TIMPs, TIMP2, TIMP3, and TIMP4 have been shown to contribute to myocardial fibrosis through different mechanisms and their loss often exacerbated myocardial fibrosis [10] [11] [12] [13] [14] ; however, the role of TIMP1 has been less explored. TIMP1 can inhibit many MMPs except the membrane-bound MMPs. 2 Elevated tissue and plasma TIMP1 levels have been correlated with myocardial fibrosis and diastolic dysfunction, [15] [16] [17] and TIMP1 has been used as a biomarker for fibrosis in patients and in animal models of heart disease. 18, 19 Despite the consistent link between TIMP1 and fibrosis, it remains unknown whether TIMP1 directly promotes tissue fibrosis or whether its rise is simply a bystander alteration in this process. We investigated the role of TIMP1 in myocardial fibrosis in Abstract-Myocardial fibrosis is excess accumulation of the extracellular matrix fibrillar collagens. Fibrosis is a key feature of various cardiomyopathies and compromises cardiac systolic and diastolic performance. TIMP1 (tissue inhibitor of metalloproteinase-1) is consistently upregulated in myocardial fibrosis and is used as a marker of fibrosis. However, it remains to be determined whether TIMP1 promotes tissue fibrosis by inhibiting extracellular matrix degradation by matrix metalloproteinases or via an matrix metalloproteinase-independent pathway. We examined the function of TIMP1 in myocardial fibrosis using Timp1-deficient mice and 2 in vivo models of myocardial fibrosis (angiotensin II infusion and cardiac pressure overload), in vitro analysis of adult cardiac fibroblasts, and fibrotic myocardium from patients with dilated cardiomyopathy (DCM). Timp1 deficiency significantly reduced myocardial fibrosis in both in vivo models of cardiomyopathy. We identified a novel mechanism for TIMP1 action whereby, independent from its matrix metalloproteinase-inhibitory function, it mediates an association between CD63 (cell surface receptor for TIMP1) and integrin β1 on cardiac fibroblasts, initiates activation and nuclear translocation of Smad2/3 and β-catenin, leading to de novo collagen synthesis. This mechanism was consistently observed in vivo, in cultured cardiac fibroblasts, and in human fibrotic myocardium. In addition, after long-term pressure overload, Timp1 deficiency persistently reduced myocardial fibrosis and ameliorated diastolic dysfunction. This study defines a novel matrix metalloproteinase-independent function of TIMP1 in promoting myocardial fibrosis. As such targeting TIMP1 could prove to be a valuable approach in developing antifibrosis therapies. (Hypertension. 2017;69:1092-1103. DOI:
hypertrophic and dilated cardiomyopathies and whether its function is mediated through an MMP-dependent or MMPindependent mechanism. Here, we provide evidence from 2 in vivo models of myocardial fibrosis in Timp1-deficient mice, in vitro adult mouse cardiac fibroblasts, and myocardial specimens from patients with heart failure, showing that TIMP1 is a driving force in promoting myocardial fibrosis through a mechanism independent from its MMP-inhibitory function. We demonstrate that TIMP1 activates a signaling pathway that involves the interaction of CD63 and integrin β1, nuclear translocation of phospo-Smad2/3 and phospho-β-catenin, and expression of ECM collagens.
Methods Experimental Animals and Surgical Procedures
Wild-type (WT) and TIMP1-deficient male mice (Timp1 −/− ) in C57BL/6 background were purchased from Jackson Laboratories and bred in-house at University of Alberta. All experiments were performed in accordance with the Canadian Council on Animal Care Guidelines and regulations of Animal Care and Use Committee at University of Alberta.
Cardiac pressure overload was induced in male WT and Timp1 −/− mice (8-10 weeks of age) by transverse aortic constriction (TAC) as described previously. 10, 20 Male 8-to 9-week-old mice of either genotype received angiotensin II (Ang II, 1.5 mg/kg per day) or saline by Alzet micro-osmotic pump (Model 1002; Durect Co.) implanted dorsally and subcutaneously as before.
14,21 MMP inhibitor (MMPi), PD166793 (30 mg/kg per day) was administered by daily gavage as before. 22, 23 At the indicated time points, hearts were excised, (Optimal Cutting Temperature)-cryopreserved, or formalin-fixed for immunohistochemical analyses. Alternatively, hearts flash-frozen for molecular analyses.
Cardiac Function Assessment
Heart structure and function were assessed in post-sham/TAC hearts noninvasively by transthoracic echocardiography under anesthesia (1% isoflurane) using Vevo 3100 high-resolution imaging system equipped with a 30-MHz transducer (Visual Sonics) as described before. 10, 13, 14 Invasive hemodynamic and pressure-volume measurements were performed in anesthetized mice (2% isoflurane) post-TAC/sham using 1.2F Scisense catheter (TCP-500 Scisense Inc.).
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Human Explanted Heart Tissue
Heart tissues from patients with heart failure were procured at the time of cardiac transplantation as part of the Human Explanted Heart Program at the Mazankowski Alberta Heart Institute (Edmonton, Alberta), and healthy control hearts were obtained through the Human Organ Procurement and Exchange program (Edmonton, Alberta) as before. 25 All experiments were approved by institutional ethics committee and performed in accordance with the institutional guidelines with informed consent from all subjects.
Histological and Immunohistochemical Staining and Imaging
Immuhistochemical staining for trichrome, picrosirius red and wheat glutamine staining were performed on formalin-fixed hearts as before. 13, 14 OCT-frozen 5-µm sections were used for coimmunostaining of CD63 (R&D Mab5417; NovusNBP2-32829) and integrin β1 (Millipore Mab1900), and immunostaining for scleraxis (ab58655). Fibrosis quantification was performed on picrosirius red-stained sections as before. 13, 14 Proximity ligation assay was performed on formalin-fixed hearts or cultured fibroblasts using Duolink in situ fluorescence Sigma kit and proximity ligation assay probes for mouse (DUO92004) and for rabbit antibodies (DUO92002).
RNA Extraction and Expression Analysis
Total RNA was extracted from frozen heart tissues using TriZol reagent (Invitrogen), and mRNA expression analysis was performed by TaqMan RT-PCR (reverse transcription-polymerase chain reaction) as before, and Hprt (hypoxanthine-guanine phosphoribosyltransferase-1) as the internal control. Taqman primers and probes for procollagen I-α1 and procollagen III-α1, Timps (-1 to -4) were used as before, 10, 13, 14, 21 and for scleraxis (Scx, Assay ID: Mm01205675_ m1) purchased from ThermoFisher Scientific.
Protein Extraction, Activity Assay, Immunoblot, and Coimmunoprecipitation
Total protein was extracted using Sigma extraction buffer. 26 Fluorescent-based activity assays were performed as before (EnzCheck, Molecular Probes). 13, 14 Immunoblot analyses were performed as before. 26 Coimmunoprecipitation experiments were performed to detect CD63 and integrin β1 association. Nuclear and cytosolic protein fractionations were extracted using hypotonic lysis buffer, and purity of the nuclear and the cytosolic protein was assessed by blotting for a nuclear-specific protein (Histone) and cytosole-specific protein (Caspase 3), respectively.
Adult Cardiac Fibroblast Isolation and Culture
Adult cardiac fibroblasts were isolated from WT and Timp1 −/− mice as described previously. 13, 14 Fibroblasts were used at second passage, and serum-deprived for 24 hours before experiments. Fibroblasts from WT and Timp1 −/− mice were treated with transforming growth factor-β (10 ng/mL) or Ang II (1 µmol/L) for 24 hours.
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics 19 Software. Shapiro-Wilk test for normality and homogeneity of variance was performed for all data. Comparison of groups from different genotypes was done by 2-way ANOVA. Multiple comparisons between groups within the same genotype were performed using 1-way ANOVA followed by Bonferroni or Tukey post hoc test. Averaged values represent mean±SEM. Statistical significance determined at P<0.05.
Results
Angiotensin II-Mediated Fibrosis Is Reduced in
Timp1-Deficient Mice and Not Reversed by MMPi Treatment
Ang II infusion triggered a significant increase in interstitial and perivascular fibrosis in WT mice, whereas this fibrotic response was markedly reduced in mice lacking TIMP1 (Figure 1Ai and ii). A broad-spectrum MMPi (PD166793) did not increase myocardial fibrosis in Timp1 −/− mice, indicating that the reduced fibrosis in this group is not because of elevated MMP activities in the absence of TIMP1 (Figure 1Ai and ii).
Measurement of mRNA expression for collagen type I and collagen type III, the 2 main fibrillar collagens in the heart, showed a significant Ang II-induced rise in WT but not in Timp1 −/− mice ( Figure 1B ). Gelatin zymography showed comparable levels of MMP2 and MMP9 in both genotypes ( Figure S1A in the online-only Data Supplement), whereas total gelatinase activity increased significantly but similarly in both genotypes after Ang II infusion ( Figure S1B ). In addition, Ang II-induced myocardial hypertrophy were comparable between WT and Timp1 −/− mice as assessed by heart weight:tibial length ratio, and expression of molecular markers of hypertrophy (atrial natriuretic peptide, brain natriuretic peptide, and α-skeletal actin; Figure S1C and S1D). Ang II infusion induced a marked increase in Timp1 mRNA in WT mice, whereas mRNA expression of other Timps was comparable between the 2 genotypes ( Figure S1E ). These data indicate that TIMP1 deficiency suppressed the Ang II-mediated myocardial fibrosis but not hypertrophy, perhaps not because of increased MMP activity because MMPi treatment did not alleviate the differential collagen accumulation in WT and Timp1 −/− hearts. We further examined whether TIMP1 deficiency could reduce proliferation or migration of cardiac fibroblasts, thereby suppressing the fibrosis response. Using the wound healing (scratch) assay and adult cardiac fibroblasts from WT and Timp1
−/− mice, we found that the rate of wound healing (closure of the scratched area) was not significantly different between the genotypes ( Figure S2A ). Consistently, expression of α-smooth muscle actin, a marker of myofibroblast transformation, was not different between WT and Timp1 −/− hearts after Ang II infusion ( Figure S2B) . Therefore, the reduced myocardial collagen production and deposition in Timp1 −/− -Ang II mice could not be because of suppressed cardiac fibroblast proliferation or migration in these mice.
Loss of TIMP1 Ameliorates Myocardial Fibrosis After Biomechanical Stress by Reducing Collagen mRNA Expression
Next, we examined whether the impact of Timp1 deficiency on myocardial fibrosis applies to other models of heart disease. After 2 weeks of cardiac pressure overload, significant interstitial and perivascular fibrosis was detected in WT mice, whereas this response was markedly reduced in Timp1 −/− mice (Figure 1Ci and ii). Similar to the Ang II model, mRNA expression of collagen type I and type III was markedly elevated in WT mice post-TAC but not in Timp1-deficient mice ( Figure 2B ), whereas the rise in total gelatinase activity was similar in both genotypes, and similar MMP2 and MMP9 levels were observed in both genotypes ( Figure S3Ai and ii) . Moreover, expression of α-smooth muscle actin was increased similarly in WT and Timp1 −/− hearts post-TAC ( Figure S2B ). Post-TAC myocardial hypertrophy was comparable between WT and Timp1 −/− mice after 2 and 5 weeks of TAC ( Figure S3B and S3D) . mRNA expression of Timp1 increased in WT mice at 2 and 5 weeks post-TAC, consistent with the observed myocardial fibrosis in these mice, whereas mRNA expression of other TIMPs remained comparable among groups ( Figure S3C and S3E) .
TIMP1 Mediates the Association Between CD63 and Integrin β1 in Mouse Myocardium After Pressure Overload and in Adult Cardiac Fibroblasts
CD63 is the only known cell surface receptor for TIMP1.
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TIMP1 has been reported to mediate CD63 interaction with integrin in regulating chemotaxis in neural crest cells. 28 We investigated whether TIMP1 could use a similar mechanism to modulate collagen expression in the heart. Coimmunoprecipitation experiments revealed a strong interaction between CD63 and integrin β1 in WT myocardium post-TAC; however, this interaction was significantly suppressed in Timp1 −/− -TAC hearts (Figure 2Ai and ii). Consistently, proximity ligation assay ( Figure 2B ) and coimmunostaining ( Figure 2C ) further confirmed a significantly greater increase in colocalization of CD63 and integrin β1 after pressure overload in WT compared with TIMP1-deficient mice.
Fibroblasts are key players in ECM remodeling as they are the main cell source for production of fibrillary collagens and other ECM proteins. Therefore, we investigated whether the observed TIMP1-mediated CD63-integrin β1 interaction occurs in cardiac fibroblasts. In cultured adult cardiac fibroblasts from WT and Timp1 −/− mice, treatment with profibrotic agents Ang II or transforming growth factor-β1 increased the interaction between CD63 and integrin β1 in WT, but not in Timp1 −/− fibroblasts as determined by coimmunoprecipitation ( Figure 3A) , proximity ligation assay ( Figure 3B) , and coimmunostaining for these 2 molecules ( Figure 3C ). These data collectively support the notion that TIMP1 is required for the CD63-integrin β1 interaction.
TIMP1-Mediated CD63-Integrin β1 Interaction Correlates With Myocardial Fibrosis in Patients With DCM
Because TIMP1 has been consistently linked to myocardial fibrosis in patients with DCM, 15, 17 we investigated whether TIMP1-mediated CD63-integrin β1 interaction is also present in fibrotic human myocardium. As anticipated, DCM hearts exhibited marked fibrosis compared with nonfailing control hearts as evident by picrosirius red and trichrome-stained sections (Figure 4Ai and ii). We performed coimmunoprecipitation on the membrane and the cytosolic protein fractions of the human myocardial specimens and found a strikingly higher CD63-integrin β1 interaction in the DCM membrane protein fraction (but not cytosolic fraction) compared with the nonfailing control hearts (Figure 4Bi ), along with greater TIMP1 protein levels in this group (Figure 4Biii ).
TIMP1 Activates a Signaling Pathway That Involves Activation and Nuclear Translocation of Smad2/3 and β-Catenin
Next, we investigated the downstream signaling pathway that could lead to induction of mRNA expression of collagen and subsequently tissue fibrosis. Smad2/3 is a profibrotic transcription factor that is activated in response to various profibrosis stimuli, often as a part of transforming growth factor-β pathway activation, which is a key mechanism of fibrosis in various tissue. Consistent with the greater degree of fibrosis in WT-TAC hearts, phospho-to-total Smad 2/3 ratio was significantly higher in WT than in Timp1 −/− hearts post-TAC ( Figure 5A ). It has also been reported that phospho-Smad2/3 can associate with phosphorylated β-catenin (Y654) 29 or scleraxis 30 before its nuclear localization. β-catenin is associated with cadherins and other transmembrane proteins that can interact with CD63. 31, 32 Immunoblotting for phospho-β-catenin and phosphor-Smad2/3 on the nuclear and cytosolic protein fractions from WT and Timp1 −/− hearts showed a markedly greater level of nuclear translocation for phosphoSmad2/3 and phospho-β-catenin after pressure overload in WT but not in Timp1 −/− mice ( Figure 5B ). Together, these data show a coordinated function between the transforming growth factor-β pathway and the TIMP1-mediated CD63-β-catenin association that lead to transcriptional induction of collagen ( Figure 5C ).
Assessment of contribution of scleraxis showed that in myocardial specimens from patients with DCM, scleraxis levels were markedly higher compared with nonfailing control hearts ( Figure S4A ). After TAC, scleraxis levels increased more in WT than in Timp1 −/− hearts ( Figure S4B and S4C). However, nuclear translocation of scleraxis was not altered with Timp1 deficiency (Figure S4D ), suggesting that scleraxis may not be a key player in TIMP1-mediated collagen synthesis. Purity of the nuclear and non-nuclear protein fractions in these experiments was confirmed by immunoblotting for histone (nuclear) and caspase 3 (cytoplasm) proteins ( Figure S5 ).
Absence of TIMP1 Has Long-Term Beneficial Effects After Cardiac Pressure Overload
We investigated whether the suppressed fibrosis in Timp1-deficient mice exerts protective (or deleterious) effects over long-term after cardiac pressure overload. The suppressed myocardial fibrosis in Timp1 −/− mice persisted up to 9 weeks post-TAC ( Figure 6A ), whereas these mice also exhibited ameliorated cardiomyopathy compared with WT-TAC mice. At 9 weeks post-TAC, myocardial hypertrophy, measured by heart weight:tibial length ( Figure 6B) , myocyte crosssectional area ( Figure S6A ), disease markers (α-skeletal actin, β-myosin heavy chain, and brain natriuretic peptide), and pulmonary edema, a measure of heart failure ( Figure 6C and 6D) were significantly lower in Timp1 −/− -TAC than in WT-TAC mice.
Assessment of cardiac structure and function by noninvasive echocardiography (Figure S6B and S6C ; Table S1 ) showed that biomechanical stress (TAC) significantly reduced left ventricular (LV) contractility (ejection fraction; i), resulted in LV dilation (ii, iii) and left atrial enlargement, which is a marker of LV diastolic dysfunction and heart failure (iv) in WT mice. Interestingly, Timp1 deficiency ameliorated the decrease in ejection fraction and LV dilation and improved the parameters of diastolic dysfunction, E/E′ ratio and left atrial enlargement. Invasive hemodynamic measurements further demonstrated partially preserved cardiac function in Timp1 −/− -TAC mice as evidenced by a leftward shift in the pressurevolume loop compared with WT-TAC mice (Figure 6Ei) , and the lack of elevated LV end-diastolic volume (Figure 6Eii) .
Consistent with the less severe diastolic dysfunction in
Timp1
−/− mice, LV stiffness (end-diastolic pressure-volume slope) was enhanced in WT-TAC but not in Timp1 −/− -TAC mice (Figure 6Eiii ). These data collectively indicate that the absence of TIMP1 prevented decompensation and heart failure after long-term pressure overload.
Discussion
Tissue fibrosis is a key pathogenic feature of end-organ failure in various organs, including heart failure. This study reveals a new function for TIMP1 in promoting myocardial fibrosis, which can be helpful in treating and managing fibrosis and heart disease. Elevated plasma TIMP1 levels have been consistently linked to myocardial fibrosis in patients 15, 33 and in animal models, 11 and it has been proposed to be a reliable biomarker for tissue fibrosis. 15, 17 TIMP1 is best known as an inhibitor of soluble MMPs (and not of membranebound-MMPs), 2 and as such it is often assumed that a rise in TIMP1 promotes fibrosis by inhibiting MMPs and their ECM-degrading function. In this study, we demonstrate that Timp1 deficiency suppresses myocardial fibrosis through an MMP-independent mechanism. Using 2 in vivo models of myocardial fibrosis, in vitro adult cardiac fibroblast cultures, and human myocardial specimens, we demonstrate that TIMP1 promotes myocardial fibrosis by mediating the interaction between CD63 and integrin β1 on fibroblasts, activation and nuclear translocation of Smad2/3 and β-catenin, and induction of de novo mRNA expression of collagens type I and III. Interestingly, the absence of other TIMPs (TIMP2, TIMP3, and TIMP4) resulted in enhanced myocardial fibrosis in different heart disease models, 6, 10, 12, 23 making TIMP1 a unique member of the TIMP family to have an inverse impact on myocardial fibrosis.
Integrin β1 in cardiac fibroblasts has been shown to contribute to heart failure, 34 as its levels rise in response to profibrotic factors triggering collagen expression. 35, 36 Contribution of fibroblast integrins to fibrosis has also been reported in other organs. 37 CD63 is a membrane protein present on the cell surface of various cell types, and although it is abundant on endosomes and lysosomes, 38 it is well-recognized for its lysosome-independent functions. 39 CD63 is the only known cell surface receptor for TIMP1. 27 In stellate cells in the liver, binding of TIMP1 to CD63-integrin β1 complex promoted cell migration, 40 whereas this interaction inhibited tumor growth through activating the FAK (focal adhesion kinase) and PI3K (phosphoinositide-3 kinase) signaling pathways 27, 41, 42 and regulated chemotaxis in neural crest cells. 28 Our study is the first to report a novel function of TIMP1 in induction of collagen synthesis and fibrosis in the heart by mediating the interaction between CD63 and integrin β1 in cardiac fibroblasts, leading to subsequent activation and nuclear translocation of Smad2/3 and β-catenin, and induction of collagen mRNA expression ( Figure 7C ). Scleraxis is another transcription factor that has been reported to work synergistically with Smad2/3 to trigger fibrosis. 30, 43 Although scleraxis levels were increased in the fibrotic myocardium (human and mouse), this increase was comparable between WT and TIMP1-deficient mice suggesting that Scx is not a key player in TIMP1-mediated induction of collagen synthesis and fibrosis although it could contribute to TIMP1-independent fibrosis response.
MMP-independent functions of TIMP1 and other TIMPs have been reported in different cell types. TIMP1 can promote proliferation of oligodendrocytes. 44 TIMP3 deficiency led to severe myocardial fibrosis after Ang II infusion because of post-translational regulation of matricellular proteins. 14 TIMP4 modulated cardiac recovery from ischemia-reperfusion by regulating the inflammatory response rather than by MMP inhibition. 13 In a model of MI, TIMP1-deficient mice exhibited a greater rise in MMP activity and exacerbated cardiac dysfunction compared with parallel WT mice, and treatment with an MMPi improved the cardiac dysfunction in Timp1 −/− -MI mice. 45, 46 Therefore, the function of TIMP1 in cardiac response to MI seems to be primarily through its MMP-inhibitory function. However, after pressure overload or Ang II infusion, lack of TIMP1 did not result in an additional rise in MMP activity, and consistently, MMPi treatment did not reverse the suppressed myocardial fibrosis in Timp1 −/− mice. It is important to note that the mechanism of cardiac fibrosis after MI is distinct from that after pressure overload, as the former is reparative fibrosis (wound healing) [3] [4] [5] and the latter is reactive fibrosis.
2
After MI, MMP activity peaks shortly after the onset of MI and drives the remodeling of the infarcted myocardium, 22 whereas the rise of MMP activities after pressure overload occurs gradually such that its impact on tissue remodeling may not be as stark as in post-MI. Hence, it is not surprising that TIMP1 plays distinct functions in cardiac recovery from MI compared with pressure overload. Furthermore, we reported previously that TIMP1 deficiency does not alter Ang II-induced hypertension 47 ; therefore, the reduced fibrosis in Timp1 −/− -Ang II mice is not because of suppressed hypertension. The antifibrotic effects of TIMP1 deficiency has longterm beneficial effects as it leads to ameliorated myocardial hypertrophy, LV dilation, and systolic and diastolic dysfunctions in Timp1 −/− mice. In conclusion, this study defines a novel function of TIMP1 in triggering fibrosis independent from its MMPinhibitory function and through mediating an interaction between fibroblast membrane proteins, CD63 and integrin β1. This finding is supported by data from in vivo genetic mouse models, human myocardial specimens, and in vitro cell culture. Although the cause of the cardiomyopathy in patients with DCM is different from that in murine pressure overload and Ang II infusion models, the consistent observation that TIMP1 can mediate CD63-integrin β1 interaction in correlation with myocardial fibrosis further supports the diverse applicability of this pathway to different types of nonischemic cardiomyopathies. With this new information on the role of TIMP1 in fibrosis, targeting TIMP1 could prove to be beneficial in limiting fibrosis in patients with nonischemic cardiomyopathies, which could subsequently hinder disease progression and heart failure.
Perspectives
Our study defines a novel and MMP-independent function for TIMP1 in inducing myocardial fibrosis through mediating an interaction between CD63 and integrin β1 on cardiac fibroblasts that leads to de novo expression of fibrillar collagens (I and III). Discovery of this MMP-independent function of TIMP1 in fibrosis provides new insight into developing antifibrosis therapies by targeting TIMP1. 
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